119106-85-3Relevant articles and documents
NEW FORMULATIONS CONTAINING LEUKOTRIENE RECEPTOR ANTAGONISTS
-
Page/Page column 38-40, (2020/07/25)
There is provided pharmaceutical formulations that may be used topically comprising a leukotriene receptor antagonist, a salt or a solvate thereof. Particular leukotriene receptor antagonists that may be mentioned include montelukast styrene. The formulations find particular utility in direct topical administration for the treatment of inflammation, of inflammatory disorders and/or of condition characterized by inflammation, including wounds, burns, psoriasis, haemorrhoids, acne and atopic dermatitis.